SAN DIEGO – (BUSINESS WIRE) –Escient Pharmaceuticals, Inc., a leading clinical stage platform company developing drugs targeted at Mas-associated G protein coupled receptors (MRGPRs) to address serious and unmet medical needs across a wide range of therapeutic indications, has announced today that Eric Deng, Ph.D., MBA, has joined the company as Vice President, Chemistry, Manufacturing and Controls (CMC).

“Eric’s expertise will help ensure alignment of resources and adherence to performance standards as we continue to advance our best-in-class MRGPR programs through clinical development. We are delighted to have him on the team, ”said Marcus Boehm, Ph.D., Scientific Director of Escient. “His proven track record of building global product supply networks to successfully advance new therapies from discovery to clinical development and commercialization will be invaluable to Escient as we advance our new pipeline of targeted therapies by MRGPR in multiple indications.

“Escient has a world-class team and a pipeline of tremendous potential, which gives us the unique opportunity to deliver top-notch drugs to meet unmet medical needs in a variety of therapeutic areas,” said said Dr Deng. “I am delighted to join them in their mission and to help advance drug discovery, preclinical development, clinical development and possibly the commercialization of our core programs.”

Dr Deng has over 20 years of leadership experience in manufacturing and supply chain operations in the biopharmaceutical industry with emerging and multinational companies. Prior to joining Escient, Dr Deng spent the past seven years at Ultragenyx Pharmaceutical, leading the CMC supply chain, manufacturing and interoperability teams, most recently as Senior Director of Management. of manufacturing and responsible for CMC. Previously, he was a business unit manager responsible for the overall manufacturing and supply chain operations of a Bayer HealthCare business franchise. He has also held senior operations roles at Metrika, Johnson & Johnson and Honeywell. Dr Deng obtained his doctorate. in Chemistry from Ohio State University and was a Department of Energy Postdoctoral Fellow. Dr Deng received his bachelor’s degree in chemistry from the University of Nankai and an MBA in operations management from the University of Houston. He obtained his Process Excellence Black Belt certification from Johnson & Johnson.

About Escient Pharmaceuticals

Escient Pharmaceuticals is an industry-leading, clinical-stage platform biotechnology company focused on the discovery and development of first-rate drugs targeted at Mas-associated G protein coupled receptors (MRGPR) to respond to serious and unmet medical needs across a wide range of therapeutic indications. Based in San Diego, California, Escient is led by a seasoned team of biotechnology entrepreneurs with specific expertise in GPCR drug discovery and development and funded by leading life science investors including The Column Group. , 5AM Ventures, Sanofi Ventures, Cowen Healthcare Investisseurs, Redmile Group, Perceptive Advisors, Osage University Partners and Altitude Life Science Ventures.

Visit www.escientpharma.com to learn more.